i50K is an evolution of HD 50K, the trusted genomic testing platform from Zoetis. Because this platform uses imputation to enable the same improvements in accuracy of GE-EPDs as HD 50K to inform a variety of selection, mating and marketing decisions at a lower price, it provides a high degree of value to breeders.
“i50K results support GE-EPDs and offer notable increases in accuracy for the full scope of traits evaluated in young Limousin and Lim-Flex bulls and females,” Dr. Andersen added. “In the immediate term, compared to other options available, development of i50K for Limousin and Lim-Flex included more animals, explains more genetic variation for more traits, and generally results in higher accuracy GE-EPDs for non-parent animals.” Longer term, Limousin and Lim-Flex genotypes from i50K will be directly integrated into the International Genetic Solutions launch and weekly Biometric Open Language Tools (BOLT) genetic evaluation and multi-breed GE-EPDs.
“The key immediate advantages of Zoetis i50K include robust GE-EPDs for four additional traits that have not previously been available—scrotal circumference, stayability, docility and yield grade—as well as more explained variation for growth trait predictions, including weaning weight and yearling weight,” said Dr. Andersen.
With this valuable information, breeders and commercial users of Limousin and Lim-Flex genetics can more dependably:
- Buy and sell bulls based on higher accuracy GE-EPDs for traits that drive net returns
- Select and purchase semen from young sire prospects, with fewer disappointments
- Select and breed replacement females and cows to accentuate strengths and correct genetic weaknesses
- Select and breed donors for embryo transfer (ET) and in vitrofertilization (IVF) programs
i50K also guides decisions as to whether bull calves should be performance tested and eventually sold as breeding stock for a variety of more clearly determined purposes.
“The availability of i50K to Limousin and Lim-Flex breeders is a testament to the dedication of NALF to adopt advanced genetic evaluation technology for the delivery of GE-EPDs and offer testing options to members,” said Dr. Andersen. “In addition, with the new distribution agreement between NALF and Zoetis, members have access to the full range of Zoetis genomic products.”
Zoetis (NYSE: ZTS) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetisUS.com.
All trademarks are the property of Zoetis Services LLC or a related company or licensor unless otherwise noted. ©2018 Zoetis Services LLC. All rights reserved. i50K-00095